Kala's technology coats mucosal surfaces with drug-loaded particles, achieving high local drug concentrations with reduced systemic exposure. The company has demonstrated success in mucosal organs such as the respiratory tract, eye, and cervicovaginal tract, and is focused on advancing its internal pipeline while collaborating with select partners. Kala's two marketed products are EYSUVIS and INVELTYS, both innovative therapies for diseases of the eye.